Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Modern Pathology

• Publication date

  2005-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/modpathol.3800396PMID 15920553
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diffuse large B-cell lymphoma.

  2007cited by this paper
• Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma.

  2004cited by this paper
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

  2004cited by this paper
• Building an outcome predictor model for diffuse large B-cell lymphoma.

  2004cited by this paper
• Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma

  2004cited by this paper
• Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

  2003cited by this paper
• Prognostic significance of bcl‐2, bax, and p53 expression in diffuse large B‐cell lymphoma

  2003cited by this paper
• Variability in immunophenotype in diffuse large B‐cell lymphoma and its clinical relevance

  2003cited by this paper
• Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues

  2003cited by this paper
• Regulation of Lymphocyte Apoptosis by Interferon Regulatory Factor 4 (IRF-4)

  2003cited by this paper
• Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.

  2003cited by this paper
• Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil.

  2003cited by this paper
• Immunohistochemical analysis of B‐cell lymphoma using tissue microarrays identifies particular phenotypic profiles of B‐cell lymphomas

  2003cited by this paper
• Increased Expression of the bcl6 and CD10 Proteins Is Associated with Increased Apoptosis and Proliferation in Diffuse Large B-Cell Lymphomas

  2003cited by this paper
• Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.

  2003cited by this paper
• A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

  2003cited by this paper
• Diffuse large B‐cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification

  2002cited by this paper
• The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

  2002cited by this paper
• Acetylation inactivates the transcriptional repressor BCL6

  2002cited by this paper
• Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B‐cell lymphoma

  2002cited by this paper
• Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.

  2002cited by this paper
• Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes

  2002cited by this paper
• p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.

  2002cited by this paper
• Chromosomal Imbalances in Diffuse Large B-Cell Lymphoma Detected by Comparative Genomic Hybridization

  2002cited by this paper
• Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

  2001cited by this paper
• Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.

  2001cited by this paper
• Analysis of MUM1/IRF4 Protein Expression Using Tissue Microarrays and Immunohistochemistry

  2001cited by this paper
• Causes and Consequences of BCL2 Overexpression in Diffuse Large B-Cell Lymphoma

  2001cited by this paper
• CD10 and Bcl10 expression in diffuse large B‐cell lymphoma: CD10 is a marker of improved prognosis

  2001cited by this paper
• Diffuse large cell lymphoma.

  2001cited by this paper
• The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma.

  2001cited by this paper
• Molecular and immunological dissection of diffuse large B cell lymphoma : CD5[+], and CD5[-] with CD10[+] groups may constitute clinically relevant subtypes

  2000cited by this paper
• A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.

  2000cited by this paper
• Diffuse large-cell lymphoma.

  2000cited by this paper
• Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

  2000cited by this paper
• CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.

  2000cited by this paper
• BCL2 overexpression in diffuse large B-cell lymphoma.

  1999cited by this paper
• Prognostic clinicopathologic factors, including immunologic expression in diffuse large B‐cell lymphomas

  1999cited by this paper
• Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5− with CD10+ groups may constitute clinically relevant subtypes

  1999cited by this paper
• Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins.

  1998cited by this paper
• Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.

  1998cited by this paper
• Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

  1997cited by this paper
• Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.

  1996cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper

• Real-world single-center experience with pixantrone in DLBCL prior to its withdrawal: clinical outcomes and exploratory immunologic observations.

  2026cites this paper
• Diffuse Large B Cell Lymphoma: Immunohistochemical Classification According to Hans Algorithm and Association With Outcome in A Moroccan Institution

  2024cites this paper
• Comparative analysis of the aberrant immunophenotype and clinical characteristics in dogs with lymphoma: a study of 27 cases

  2023cites this paper
• Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma

  2023cites this paper
• Investigating In Situ Expression of c-MYC and Candidate Ubiquitin-Specific Proteases in DLBCL and Assessment for Peptidyl Disruptor Molecule against c-MYC-USP37 Complex

  2023cites this paper
• Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases—A Possible Association with High Rheumatoid Arthritis Disease Activity

  2022cites this paper
• A Rare Case of Intravascular Large B-cell Lymphoma Presenting With Bilateral Ophthalmoplegia, Along With a Literature Review

  2022cites this paper
• Follicular lymphoma grade 3: a comprehensive review.

  2022cites this paper
• Germinal-Center B-Cell-Like (GCB) DLBCL Versus Activated B-Cell-Like (ABC) DLBCL: Biology and Treatment Approach

  2022cites this paper
• CMAR_A_345745 925..935

  2022cites this paper
• MUM1 Expression versus Hans Algorithm to Predict Prognosis in Indonesian Diffuse Large B-Cell Lymphoma Patients Receiving R-CHOP

  2022cites this paper
• Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma

  2022cites this paper
• Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis.

  2022cites this paper
• Comparative analysis of immunohistochemical features of nodal versus extranodal diffuse large B cell lymphoma with respect to cell-of-origin classification

  2022cites this paper
• Germinal Center Cells Turning to the Dark Side: Neoplasms of B Cells, Follicular Helper T Cells, and Follicular Dendritic Cells

  2021cites this paper
• Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases

  2021cites this paper
• Role of MUM-1 immunohistochemistry in prognosis of primary gastrointestinal diffuse large cell lymphoma

  2021cites this paper
• MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience

  2020cites this paper
• In situ BCL2 expression is an independent prognostic factor in HIV‐associated DLBCL, a LYMPHOVIR cohort study

  2020cites this paper
• Intravascular Large B-cell Lymphoma: A Report of Two Cases

  2020cites this paper
• Intravascular large B-cell lymphoma

  2020cites this paper
• Primary Gastric Diffuse Large B-Cell Lymphoma: Prognostic Factors in the Immuno-Oncology Therapeutics Era

  2020cites this paper
• Expression of Foxp3 and interleukin-7 receptor and clinicopathological characteristics of patients with diffuse large B-cell lymphoma

  2020cites this paper
• Physical torment: A predisposition for diffuse B-cell lymphoma

  2019cites this paper
• Treatment outcome and prognostic factors in PCNSL

  2019cites this paper
• Cellular and molecular factors in the pathogenesis of systemic autoimmunity and comorbidities

  2019cites this paper
• Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-east Asian population: a single center experience and review of the literature

  2019cites this paper
• Chapter 7 Prognostic impact of germinal center – associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma

  2019cites this paper
• Immunostains: Hematopoietic System

  2019cites this paper
• Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B‐Cell Lymphoma

  2019cites this paper
• A modular transcriptome map of mature B cell lymphomas

  2019cites this paper
• The association of the coexpression of c-myc, PTEN and t (14;18) detected by fluorescent in situ hybridization with high proliferation index in diffuse large B cell lymphoma

  2018cites this paper
• Primary testicular diffuse large B-cell lymphomas have activated B cell-like subtype characteristics

  2018cites this paper
• Morphology and Immunophenotype of Chronic Lymphocytic Leukemia

  2018cites this paper
• PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

  2018cites this paper
• Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

  2018cites this paper
• BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma

  2018cites this paper
• Over expression of circulating miR-155 predicts prognosis in diffuse large B-cell lymphoma.

  2018cites this paper
• Clinical significance and functional validation of inorganic pyrophosphatase in diffuse large B cell lymphoma in humans

  2018cites this paper
• The phenotypes of germinal center B-cell-like ( GCB ) and non-GCB failed to predict the survival of patients with diffuse large B-cell lymphoma in the rituximab era

  2017cites this paper
• MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL

  2017cites this paper
• Ki-67 and subtype as prognostic and predictive markers of diffuse large B-Cell lymphoma

  2017cites this paper
• Prognostic analysis of DLBCL patients and the role of upfront ASCT in high-intermediate and high-risk patients

  2017cites this paper
• Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry.

  2017cites this paper
• WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

  2017cites this paper
• KLHL6 Is Preferentially Expressed in Germinal Center–Derived B-Cell Lymphomas

  2017cites this paper
• B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients

  2017cites this paper
• MicroRNAs in diffuse large B-cell lymphoma.

  2016cites this paper
• Tumour associated macrophages in Diffuse Large B cell lymphoma

  2016cites this paper
• Potential New Drugs in Lymphoma

  2016cites this paper
• Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma

  2016influential citation
• Introduction The importance of Myd 88 L 265 P mutation , clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia

  2016cites this paper
• Higher intensity of Low Molecular Weight Protein Tyrosine Phosphatase/ ACP-1 in survivors of patients diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) compared to non-survivors

  2016cites this paper
• Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist’s Point of View

  2016cites this paper
• Potential New Drugs in Lymphoma

  2016cites this paper
• The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.

  2016cites this paper
• Primary and metastatic lymphoma of the testis – a review of the literature

  2016cites this paper
• A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphoma Molecular Subtypes: A Cell of Origin-Driven Review.

  2016cites this paper
• Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era

  2016cites this paper
• Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.

  2015cites this paper
• Evaluation of BCL6 and MUM1 Expression in Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Their Correlation with Staging and Prognosis of the Disease

  2015cites this paper
• Regulated cell death in diagnostic histopathology.

  2015cites this paper
• Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.

  2015cites this paper
• Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease

  2015cites this paper
• Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival.

  2015cites this paper
• Prognostic value of CD10, BCL-6, MUM-1, and CD138 in diffuse large B-cell lymphoma

  2015influential citation
• miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.

  2015cites this paper
• A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

  2015cites this paper
• SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients

  2015cites this paper
• Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma

  2015cites this paper
• Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis.

  2014cites this paper
• Expression of lipid signalling molecules in epithelial and lymphoid malignancies

  2014cites this paper
• Exploring biomarkers from the tumour and the microenvironment in Diffuse Large B-cell Lymphoma.

  2014cites this paper
• Current Perspectives in Genetics of “Double-Hit” Lymphoma with Possible Clinical Implications

  2014cites this paper
• Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay

  2014cites this paper
• Prognostic Markers in Diffuse Large B-cell Lymphoma

  2014cites this paper
• UNCOMMON TUMORS OF THE TESTIS

  2014cites this paper
• Ocular and Adnexal Lymphoma: Molecular Pathology

  2014cites this paper
• Incidence of lymphoma associated with underlying lupus: lessons learned from observational studies

  2014cites this paper
• Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP

  2014cites this paper
• Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma

  2013cites this paper
• Large Cell Lymphoma: Correlation of HIV Status and Prognosis with Differentiation Profiles Assessed by Immunophenotyping

  2013cites this paper
• Cell Origin Subtypes Predict Outcomes in Localized-Stage Diffuse Large B-Cell Lymphoma Treated with Curative Radiotherapy

  2013cites this paper
• FACULTE DE MEDECINE DE TOURS

  2013cites this paper
• and Treatment With Survival Canine Lymphomas : Association of Classification Type , Disease Stage , Tumor Subtype , Mitotic Rate

  2013cites this paper
• Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma.

  2013cites this paper
• Immunoblastic morphology as a possible prognostic indicator for the outcome of the patients with diffuse large B cell lymphoma in era of the rituximab based treatment: single centre experience

  2013cites this paper
• Correlation Between Immunophenotype Classification and Clinicopathological Features in Chinese Patients with Primary Gastric Diffuse Large B-Cell Lymphoma

  2013cites this paper
• Central nervous system lymphoma in immunocompetent patients: the North Shore-Long Island Jewish Health System experience.

  2013cites this paper
• Testicular and testicular adnexa tumors in the elderly

  2013cites this paper
• Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies.

  2013cites this paper
• Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab

  2013influential citation
• Canine Lymphomas

  2013cites this paper
• Genetic and Immunohistochemical Characterization of Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma

  2013cites this paper
• Diffuse large B-cell lymphoma, not otherwise specified of the palate: A case report

  2013cites this paper
• Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis

  2013cites this paper
• Immunophenotype classification and therapeutic outcomes of Chinese primary gastrointestinal diffuse large B-cell lymphoma

  2012cites this paper
• Clinical and functional aspects of microRNA regulation in human cancers

  2012cites this paper
• Diffuse large B-cell lymphoma.

  2012cites this paper
• Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry

  2012cites this paper